JW (CAYMAN) THERAPEUTICS CO. LTD revenue breakdown overview

JW (CAYMAN) THERAPEUTICS CO. LTD revenue for the last year amounted to 168.40 M HKD, the most of which — 171.54 M HKD — came from its highest performing source at the moment, Autologous Chimeric Antigen Receptor T-cell Immunotherapy, the year earlier bringing 192.11 M HKD. The greatest contribution to the revenue figure was made by China — last year it brought JW (CAYMAN) THERAPEUTICS CO. LTD 171.54 M HKD, and the year before that — 192.11 M HKD.